Pulmonary hypertension (PH) is a complex, progressive condition characterized by elevated pulmonary artery pressure and pulmonary vascular resistance. This article provides a comprehensive overview of the fundamental aspects of PH, including its pathophysiology, diagnosis, and management strategies.
PH is primarily a disorder of the pulmonary vasculature. It is characterized by vasoconstriction, vascular remodeling, and in situ thrombosis. These changes lead to increased pulmonary vascular resistance and subsequently elevated pulmonary artery pressure. The disease is classified into five groups based on the underlying cause, each with distinct pathophysiological mechanisms.
Diagnosis of PH involves a combination of clinical evaluation, echocardiography, and right heart catheterization. Echocardiography is a non-invasive tool used for initial assessment, while right heart catheterization is the gold standard for confirming the diagnosis. Additional tests such as pulmonary function tests, chest radiographs, and CT scans may be required to identify the underlying cause.
Treatment of PH is multifaceted and depends on the underlying cause. General measures include lifestyle modifications, oxygen therapy, and anticoagulation. Specific therapies target the three main pathways involved in the pathogenesis: the nitric oxide, endothelin, and prostacyclin pathways. Lung transplantation may be considered in severe, refractory cases.
PH is a complex disease with a multifactorial pathogenesis and diverse clinical manifestations. Understanding its fundamentals is crucial for its early diagnosis and effective management. As physicians, maintaining a high index of suspicion and adopting a systematic approach to diagnosis can significantly improve patient outcomes. Continuous research in this field is essential to develop more effective therapeutic strategies.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation